Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.

Cryptococcal meningitis (CM) remains a leading cause of death for HIV-infected individuals in sub-Saharan Africa. Improved treatment strategies are needed if individuals are to benefit from the increasing availability of antiretroviral therapy. We investigated the factors associated with mortality i...

Full description

Bibliographic Details
Main Authors: Josephine V J Lightowler, Graham S Cooke, Portia Mutevedzi, Richard J Lessells, Marie-Louise Newell, Martin Dedicoat
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2799667?pdf=render
_version_ 1818969841423351808
author Josephine V J Lightowler
Graham S Cooke
Portia Mutevedzi
Richard J Lessells
Marie-Louise Newell
Martin Dedicoat
author_facet Josephine V J Lightowler
Graham S Cooke
Portia Mutevedzi
Richard J Lessells
Marie-Louise Newell
Martin Dedicoat
author_sort Josephine V J Lightowler
collection DOAJ
description Cryptococcal meningitis (CM) remains a leading cause of death for HIV-infected individuals in sub-Saharan Africa. Improved treatment strategies are needed if individuals are to benefit from the increasing availability of antiretroviral therapy. We investigated the factors associated with mortality in routine care in KwaZulu-Natal, South Africa.A prospective year long, single-center, consecutive case series of individuals diagnosed with cryptococcal meningitis 190 patients were diagnosed with culture positive cryptococcal meningitis, of whom 186 were included in the study. 52/186 (28.0%) patients died within 14 days of diagnosis and 60/186 (32.3%) had died by day 28. In multivariable cox regression analysis, focal neurology (aHR 11 95%C.I. 3.08-39.3, P<0.001), diastolic blood pressure<60 mmHg (aHR 2.37 95%C.I. 1.11-5.04, P=0.025), concurrent treatment for tuberculosis (aHR 2.11 95%C.I. 1.02-4.35, P=0.044) and use of fluconazole monotherapy (aHR 3.69 95% C.I. 1.74-7.85, P<0.001) were associated with increased mortality at 14 and 28 days.Even in a setting where amphotericin B is available, mortality from cryptococcal meningitis in this setting is high, particularly in the immediate period after diagnosis. This highlights the still unmet need not only for earlier diagnosis of HIV and timely access to treatment of opportunistic infections, but for better treatment strategies of cryptococcal meningitis.
first_indexed 2024-12-20T14:27:00Z
format Article
id doaj.art-e9f0cad0cd2e47d281482391d76e1ed1
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-20T14:27:00Z
publishDate 2010-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-e9f0cad0cd2e47d281482391d76e1ed12022-12-21T19:37:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-01-0151e863010.1371/journal.pone.0008630Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.Josephine V J LightowlerGraham S CookePortia MutevedziRichard J LessellsMarie-Louise NewellMartin DedicoatCryptococcal meningitis (CM) remains a leading cause of death for HIV-infected individuals in sub-Saharan Africa. Improved treatment strategies are needed if individuals are to benefit from the increasing availability of antiretroviral therapy. We investigated the factors associated with mortality in routine care in KwaZulu-Natal, South Africa.A prospective year long, single-center, consecutive case series of individuals diagnosed with cryptococcal meningitis 190 patients were diagnosed with culture positive cryptococcal meningitis, of whom 186 were included in the study. 52/186 (28.0%) patients died within 14 days of diagnosis and 60/186 (32.3%) had died by day 28. In multivariable cox regression analysis, focal neurology (aHR 11 95%C.I. 3.08-39.3, P<0.001), diastolic blood pressure<60 mmHg (aHR 2.37 95%C.I. 1.11-5.04, P=0.025), concurrent treatment for tuberculosis (aHR 2.11 95%C.I. 1.02-4.35, P=0.044) and use of fluconazole monotherapy (aHR 3.69 95% C.I. 1.74-7.85, P<0.001) were associated with increased mortality at 14 and 28 days.Even in a setting where amphotericin B is available, mortality from cryptococcal meningitis in this setting is high, particularly in the immediate period after diagnosis. This highlights the still unmet need not only for earlier diagnosis of HIV and timely access to treatment of opportunistic infections, but for better treatment strategies of cryptococcal meningitis.http://europepmc.org/articles/PMC2799667?pdf=render
spellingShingle Josephine V J Lightowler
Graham S Cooke
Portia Mutevedzi
Richard J Lessells
Marie-Louise Newell
Martin Dedicoat
Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
PLoS ONE
title Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
title_full Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
title_fullStr Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
title_full_unstemmed Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
title_short Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
title_sort treatment of cryptococcal meningitis in kwazulu natal south africa
url http://europepmc.org/articles/PMC2799667?pdf=render
work_keys_str_mv AT josephinevjlightowler treatmentofcryptococcalmeningitisinkwazulunatalsouthafrica
AT grahamscooke treatmentofcryptococcalmeningitisinkwazulunatalsouthafrica
AT portiamutevedzi treatmentofcryptococcalmeningitisinkwazulunatalsouthafrica
AT richardjlessells treatmentofcryptococcalmeningitisinkwazulunatalsouthafrica
AT marielouisenewell treatmentofcryptococcalmeningitisinkwazulunatalsouthafrica
AT martindedicoat treatmentofcryptococcalmeningitisinkwazulunatalsouthafrica